Paper498145
Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry.
Rosenberg B. Cancer Treat Rep, 1979. Cited by 118 papers, by iCite.
Cite this record
ConductScience Library. Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry. Papers, record 498145. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/498145
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Cisplatin | Major topic |
| Animals | |
| DNA | |
| Guanine | |
| Mice | |
| Neoplasms, Experimental | |
| Stereoisomerism | |
| Structure-Activity Relationship | |
| Water |
Source PubMed
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 118 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39106540 | Repair of genomic interstrand crosslinks. | DNA Repair (Amst) | 2024 | https://conductscience.org/library/papers/39106540 | PubMed |
| 34097405 | Internal and External Influences on Stability and Ligand Exchange Reactions in Bromido[3-ethyl-4-aryl-5-(2-methoxypyridin-5-yl)-1-propyl-1,3-dihydro-2H-imidazol-2-ylidene]gold(I) Complexes. | Inorg Chem | 2021 | https://conductscience.org/library/papers/34097405 | PubMed |
| 33622870 | Combination Cancer Therapy of a Del1 Fragment and Cisplatin Enhanced Therapeutic Efficiency In Vivo. | In Vivo | 2021 | https://conductscience.org/library/papers/33622870 | PubMed |
| 31458267 | Metallothionein: An Aggressive Scavenger-The Metabolism of Rhodium(II) Tetraacetate (Rh2(CH3CO2)4). | ACS Omega | 2018 | https://conductscience.org/library/papers/31458267 | PubMed |
| 27079977 | Insights into RNA binding by the anticancer drug cisplatin from the crystal structure of cisplatin-modified ribosome. | Nucleic Acids Res | 2016 | https://conductscience.org/library/papers/27079977 | PubMed |
| 21931655 | Bioluminescence-based high-throughput screen identifies pharmacological agents that target neurotransmitter signaling in small cell lung carcinoma. | PLoS One | 2011 | https://conductscience.org/library/papers/21931655 | PubMed |
| 16600465 | Copper(II) and manganese(III) complexes of N'-[(2-hydroxy phenyl) carbonothioyl] pyridine-2-carbohydrazide: novel therapeutic agents for cancer. | Biochimie | 2006 | https://conductscience.org/library/papers/16600465 | PubMed |
| 12488594 | Antitumorigenic Evaluation of Thalidomide Alone and in Combination with Cisplatin in DBA2/J Mice. | J Biomed Biotechnol | 2002 | https://conductscience.org/library/papers/12488594 | PubMed |
| 8630273 | Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8630273 | PubMed |
| 7242687 | Intracellular distribution of titanium after treatment with the antitumor agent titanocene dichloride: on electron energy loss spectroscopic study. | Naturwissenschaften | 1981 | https://conductscience.org/library/papers/7242687 | PubMed |
| 6891949 | "Two route infusion chemotherapy" using cis-Diamminedichloroplatinum (II) and its antidote, sodium thiosulfate, for metastatic liver tumors in rats. | Jpn J Surg | 1982 | https://conductscience.org/library/papers/6891949 | PubMed |
| 6824567 | Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6824567 | PubMed |
| 3910609 | Comparative cytotoxicity between cisplatin and second generation platinum analogs. | Invest New Drugs | 1985 | https://conductscience.org/library/papers/3910609 | PubMed |
| 2729945 | Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats. | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2729945 | PubMed |
| 2660897 | The effect of reduced osmolarity on platinum drug toxicity. | Br J Cancer | 1989 | https://conductscience.org/library/papers/2660897 | PubMed |
| 2381427 | Differential effects of cisplatin on mouse hepatic and renal mitochondrial DNA. | Mol Cell Biochem | 1990 | https://conductscience.org/library/papers/2381427 | PubMed |
| 2347043 | Evidence for lack of mitochondrial DNA repair following cis-dichlorodiammineplatinum treatment. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2347043 | PubMed |
| 2178792 | A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2178792 | PubMed |
| 1568289 | Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin. | Cancer Chemother Pharmacol | 1992 | https://conductscience.org/library/papers/1568289 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/498145
GET https://conductscience.org/api/papers/v1/498145/authors